Breakout Track Sessions at a Glance

TRACK C
New Generation Application of
Innovative Technology To Fuel Deals
Track Chair: TBA

The Company as Integrator: Why and How Life Science Organizations Will Move to a Networked Web of Relationships Model

Stuart Kliman, JD,
Partner & Head of Life Sciences Practice Area, Vantage Partners

Case Study: Drug Delivery Companies –
Life Cycle Management Evolution?

Gary Liversidge, PhD
Sr. Director, Commercial Development, Elan Drug Technologies

Case Study: Drug Delivery Solutions for Specialized Populations: Slow Release Inhaled Ciprofloxacin for Treatment of Respiratory Infections in Subjects with Severe Respiratory Disease

Igor Gonda
President & Chief Executive Officer, Aradigm Corporation

Negotiating Successful Deals: Road Warrior or Road Kill – It’s Your Choice

Gene Slowinski
Director, Strategic Alliance Research, Rutgers University Graduate School of Management

Hands-On Session: Drug Delivery IP Due Diligence

Clifford Davidson, Esq.
Founding Partner, Davidson, Davidson, and Kappel, LLC

2:15 Case Study: Enhancing the Oral Bioavailability of Low-Solubility Compounds: Bend Research’s Spray-Dried Dispersion (SDD) Platform

David Lyon, PhD
Vice President-Physical and Biological Sciences, Bend Research Inc.

Making Poorly Soluble Drugs Deliverable
by the Oral Route: Eurand’s Biorise® Technology

Stephen Perrett, MD, MBA
Director of Corporate Technologies and Product Portfolio, Eurand

Case Study: Deal Making & Partnering with RNAi Delivery Products

Ketan A. Mehta. Ph.D., MBA
Director, Global Drug Delivery Partnering, Roche

Panel Discusion: Is the Era of Life Cycle Extension Through Drug Delivery Winding Down?

Moderator:
Brett Zbar
Partner, Aisling Capital

Panelists:
Christopher de Souza, MBA, PhD
Vice President Business Development, Skye Pharma US Inc
Troy M. Harmon, MS, MBA
Vice President of Business Development, Eurand
Vickie O’Neil
Vice President, Research & Technology, Upsher-Smith Laboratories

Mike Desjardin, Senior Vice President, New Product Development, Jazz Pharmaceuticals

Extending the Frontiers of Transdermal Drug Delivery: An Innovative Transdermal Patch for Sustained or Bolus Delivery of Water-Soluble Proteins, Carbohydrates, and Small Drugs

Eric Tomlinson, PhD, DSc
President & CEO, Altea Therapeutics Corporation

Global Product Partnering-Looking Beyond the Borders

Willie Quinn, Sr. Director, Licensing and Acquisitions, Jazz Pharmaceuticals

How to Successfully Outsource Product Development and Manufacturing- The Pitfalls and Learnings of the Past Five Years 

Mike Desjardin, Senior Vice President, New Product Development, Jazz Pharmaceuticals

*Technology Showcase*
Four 15-minute sessions to showcase cutting-edge technology. Each session has a 10-minute presentation followed by 5-minutes Q&A.

Replacing Injectable Drugs by Pantec Biosolutions’ Painless P.L.E.A.S.E. Intraepidermal Drug Delivery Solution
Christof Böhler, PhD
CEO, Pantec Biosolutions AG

ORADURTM: Oral Controlled-Release and Abuse- Deterrent Platform Drug Delivery Technology
Jan Scicinski, PhD
Director, New Product Opportunity Assessment, DURECT Corporation

Open Tech Showcase Sessions
Do you have an innovative technology that you want to showcase at DDP?
Sign up today! Contact Sarah Scarry, sscarry@iirusa.com for more information on participating

Networking Cocktail Reception hosted by:

Understanding and Managing the Parameters that Impact Drug Delivery Product Development Times and Approval Success Rates

Josef Bossart, PhD,
Former Vice President, Business Development, Akela Pharmaceuticals and Managing Director, Bionumbers LLC

Benefits of Optimal Dosing & Reimbursement Challenges with New, More Costly Delivery Techniques

William W. Howard, PhD
CEO, The Cough Company and Former Senior VP, New Products/Business Development, Adams Respiratory Therapeutics

Nanobiotechnology for Development of Therapeutics and Diagnostics: Science and Business Perspectives

Mostafa Analoui, PhD
Head of Healthcare and Life Sciences, The Livingston Group, and Senior Vice President, Charlesson Pharmaceuticals

Panel Discusion: Large Pharma and Their
Interactions with Biotechnology Companies

Moderator:
Scott Siegel
Vice President, Corporate Development, Redpoint Bio Corporation

Panelists:
Michael Cucolo
Director, Strategic Transactions Group, Bristol-Myers Squibb
Martin E. Judge, PhD
Sourcing Director, Diabetes Research Unit, Novo Nordisk A/S
Tim Saxon
Former AVP Business Development, Wyeth Consumer Healthcare

 2:15 Investigating Sponsored and Collaborative Research as Sources of Innovation for Industry

Alan Naidoff, D.M.D, J.D., Director, Research Contracts Management, Merck & Co., Inc.

Lynne Hollyer, University of California- Berkeley

2:45 Commercial Development Strategies for Biosimilars in the USA and Europe: Regulatory & Practical Considerations for
Pre and Post Launch

James Harris
CEO, Healthcare Economics LLC

Panel Discusion:  Injectable Drug Delivery-
How Far Have We Come and Where Are We Going?

Moderator:
Jonathan Rigby
Co Founder & Vice President, Business Development, Zogenix

Panelists:
Charles Potter, PhD
Chief Executive Officer, Glide Pharmaceuticals
Mathias Romacker
Principal Business Analyst, Amgen